Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC
ǂa ǂretrospective chart review (REFLECT)
Povzetek
Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Ključne besede
napredovali nedrobnocelinčni karcinom pljuč;podatki iz resničnega življenja;srednja Evropa;advanced non-small cell lung cancer;real-world data;Central Europe;
Podatki
| Jezik: | Angleški jezik |
|---|---|
| Leto izida: | 2021 |
| Tipologija: | 1.01 - Izvirni znanstveni članek |
| Založnik: | Sage |
| UDK: | 616-006 |
| COBISS: |
89318403
|
| ISSN: | 1758-8359 |
| Št. ogledov: | 286 |
| Št. prenosov: | 94 |
| Ocena: | 0 (0 glasov) |
| Metapodatki: |
|
Ostali podatki
| Sekundarne ključne besede: | Carcinoma, non-small cell lung;Immunotherapy;Nedrobnocelični karcinom pljuč;Imunoterapija;Europe;Europe, Eastern;Evropa;Vzhodna Evropa; |
|---|---|
| Komentar vira: | Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Urška Janžič; Opis vira z dne 14. 12. 2021; |
| Strani: | str. 1-11 |
| Zvezek: | ǂVol. ǂ13 |
| Čas izdaje: | 2021 |
| DOI: | 10.1177/17588359211059874 |
| ID: | 13961696 |
Priporočena dela:
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC
2021,
ǂa ǂretrospective chart review (REFLECT)
NSCLC molecular testing in Central and Eastern European countries
2018,
ni podatka o podnaslovu
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN)
2021,
ǂa ǂretrospective analysis of patients treated through an access program
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP)
2022,
ǂa ǂretrospective analysis from an early access program
Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe
2020,
ǂa ǂ Central European Cooperative Oncology Group analysis